A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Key facts

Sponsor

BeOne Medicines

Principal Investigator

Study Director

BeOne Medicines

Intervention

Sonrotoclax(drug)

Enrollment

630 target

Eligibility

18 years · All sexes

Timeline

2025 – 2031

Study locations (30)

• Uci Health Laguna Hills, Laguna Hills, California, United States
• Chao Family Comprehensive Cancer Center, Orange, California, United States
• Stanford Cancer Institute, Palo Alto, California, United States
• Scripps Prebys Cancer Center, San Diego, California, United States
• Rocky Mountain Cancer Centers (Williams) Usor, Aurora, Colorado, United States
• Yale University, Yale Cancer Center, New Haven, Connecticut, United States
• Eastern Connecticut Hematology and Oncology, Norwich, Connecticut, United States
• Northwestern University, Chicago, Illinois, United States
• Illinois Cancer Specialists (Niles) Usor, Niles, Illinois, United States
• University of Louisville, Brown Cancer Center, Louisville, Kentucky, United States
• Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
• University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• The Cancer and Hematology Centers, Grand Rapids, Michigan, United States
• Mayo Clinic Rochester, Rochester, Minnesota, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

German CLL Study Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →